TRIAMCINOLONE ACETONIDE Drug Patent Profile

Which patents cover Triamcinolone Acetonide, and what generic alternatives are available?

Triamcinolone Acetonide is a drug marketed by Actavis Mid Atlantic, Alkem Labs Ltd, Alpharma Us Pharms, Ambix, Chartwell Rx, Cosette, Encube, Fougera Pharms, Glenmark Pharms Ltd, Macleods Pharms Ltd, Micro Labs, Morton Grove, Norvium Bioscience, Padagis Us, Pharmaderm, Pharmafair, Strides Pharma, Sun Pharma Canada, Taro, Topiderm, Alembic, Amneal, Caplin, Dr Reddys, Eugia Pharma, Hikma, Long Grove Pharms, Mylan Labs Ltd, Parnell, Sandoz, Teva Pharms Usa, Watson Labs, Beach Prods, Epic Pharma Llc, Pai Holdings Pharm, Pharmobedient, Quagen, Aurobindo Pharma Ltd, Extrovis, Glenmark Speclt, Padagis Israel, Senores Pharms, Rising, Sciegen Pharms, Apotex, and Perrigo Pharma Intl. and is included in ninety-seven NDAs.

The generic ingredient in TRIAMCINOLONE ACETONIDE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Triamcinolone Acetonide

A generic version of TRIAMCINOLONE ACETONIDE was approved as triamcinolone acetonide by SUN PHARMA CANADA on October 1^st, 1986.

Summary for TRIAMCINOLONE ACETONIDE

US Patents:	0
Applicants:	46
NDAs:	97
Finished Product Suppliers / Packagers:	69
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	305
Patent Applications:	4,494
Drug Prices:	Drug price information for TRIAMCINOLONE ACETONIDE
Drug Sales Revenues:	Drug sales revenues for TRIAMCINOLONE ACETONIDE
What excipients (inactive ingredients) are in TRIAMCINOLONE ACETONIDE?	TRIAMCINOLONE ACETONIDE excipients list
DailyMed Link:	TRIAMCINOLONE ACETONIDE at DailyMed

See drug prices for TRIAMCINOLONE ACETONIDE

See drug sales revenues for TRIAMCINOLONE ACETONIDE

Recent Clinical Trials for TRIAMCINOLONE ACETONIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Karachi Medical and Dental College	NA
Ain Shams University	PHASE4
King Edward Medical University	NA

See all TRIAMCINOLONE ACETONIDE clinical trials

Pharmacology for TRIAMCINOLONE ACETONIDE

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Medical Subject Heading (MeSH) Categories for TRIAMCINOLONE ACETONIDE

Anti-Inflammatory Agents

Glucocorticoids

Immunosuppressive Agents

Anatomical Therapeutic Chemical (ATC) Classes for TRIAMCINOLONE ACETONIDE

A01AC	Corticosteroids for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

C05AA	Corticosteroids
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D07AB	Corticosteroids, moderately potent (group II)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

D07XB	Corticosteroids, moderately potent, other combinations
D07X	CORTICOSTEROIDS, OTHER COMBINATIONS
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

H02AB	Glucocorticoids
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02	CORTICOSTEROIDS FOR SYSTEMIC USE
H	Systemic hormonal preparations, excluding sex hormones and insulins

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for TRIAMCINOLONE ACETONIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Quagen	TRIAMCINOLONE ACETONIDE	triamcinolone acetonide	LOTION;TOPICAL	213559-001	Jul 1, 2020	AT	RX	No	No
Padagis Us	TRIAMCINOLONE ACETONIDE	triamcinolone acetonide	OINTMENT;TOPICAL	087385-003	Approved Prior to Jan 1, 1982	AT	RX	Yes	Yes
Sun Pharma Canada	TRIAMCINOLONE ACETONIDE	triamcinolone acetonide	CREAM;TOPICAL	086276-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pharmaderm	TRIAMCINOLONE ACETONIDE	triamcinolone acetonide	CREAM;TOPICAL	087992-001	Jul 7, 1983		DISCN	No	No
Extrovis	TRIAMCINOLONE ACETONIDE	triamcinolone acetonide	OINTMENT;TOPICAL	011600-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Quagen	TRIAMCINOLONE ACETONIDE	triamcinolone acetonide	PASTE;DENTAL	214582-001	Dec 9, 2022	AT	RX	No	No

Market Dynamics and Financial Trajectory for Triamcinolone Acetonide

Last updated: February 19, 2026

What Drives Demand for Triamcinolone Acetonide?

Triamcinolone acetonide is a corticosteroid used to reduce inflammation and immune responses. It has established applications in dermatology, allergic reactions, and respiratory conditions. It is available via various formulations, including topical, injectable, and intralesional options. The drug's broad clinical use influences its consistent demand, especially in outpatient and hospital settings.

Market Size and Growth Trends

The global corticosteroid market, estimated at approximately USD 15 billion in 2022, includes a significant share of triamcinolone acetonide. Its specific segment is projected to grow at a compound annual growth rate (CAGR) of 4-6% through 2030. Growth drivers include:

• Increasing prevalence of inflammatory conditions.
• Greater adoption of corticosteroids for chronic disease management.
• Expansion of injectable formulations in orthopedic and dental procedures.

The topical form remains dominant, accounting for nearly 60% of the market share. Injectable forms are gaining traction in dermatology and allergy treatment centers.

Patent Life and Market Exclusivity

The original patents for triamcinolone acetonide expired in the mid-2000s. Since then, generic manufacturers dominate, reducing prices and increasing accessibility.

• Patent expiration triggered a shift toward generics.
• Several biosimilars and local equivalents have entered emerging markets.
• Market competition affects pricing, profit margins, and R&D emphasis.

Competitive Landscape

The market features multiple global and regional players:

Company	Product(s)	Market Share (est.)	Notable Developments
Pfizer	Kenalog (injectable)	35-40%	Recently expanded to biosimilar segments
Teva	Triderm (topical)	10-15%	Focus on emerging markets
Sun Pharmaceutical	Various formulations	8-12%	Launch of new formulations post-biosimilar entry
Sandoz	Generic triamcinolone acetonide injections	5-8%	Development of high-concentration versions

Regulatory and Pricing Policies

Pricing pressures surge from health authorities and payers:

• In the US, Medicaid and Medicare negotiate drug prices.
• EMEA nations emphasize cost-effectiveness assessments.
• Market access barriers include formulary restrictions and tender processes in emerging markets.

Some regions restrict high-dose injections to specialist administration, affecting sales volume.

R&D and Innovation Trajectory

New formulations aim at improved delivery and reduced side effects. Development efforts include:

• Long-acting injectable variants.
• Combination products with other anti-inflammatory agents.
• Novel delivery systems such as transdermal patches.

Investment is constrained by the drug’s mature status; innovation efforts target niche indications or enhanced formulations.

Financial Outlook

The following factors influence the financial trajectory:

• Average selling price (ASP): Declines driven by generic competition.
• Volume growth: Stable or modest increase, particularly in developing nations.
• R&D expenditure: Limited, focused on advanced delivery systems.
• Market penetration: Saturated in developed markets; growth primarily in emerging regions.

Projected revenues for the global triamcinolone acetonide market are expected to increase from USD 1.2 billion in 2022 to USD 1.6 billion by 2030, reflecting a CAGR of approximately 4.5%.

Risks and Challenges

• Price erosion due to generic competition.
• Regulatory restrictions on formulations and indications.
• Supply chain vulnerabilities influencing availability.
• Pricing policies that limit profitability in certain jurisdictions.

Key Takeaways

• Triamcinolone acetonide is central to numerous corticosteroid indications with steady demand.
• The market has matured; revenue growth relies on expanding into emerging markets and innovating delivery methods.
• Patent expiration has led to increased generics, compressing margins.
• Competition is intense among global generic manufacturers, with pricing pressure the dominant trend.
• Future opportunities hinge on niche formulation development and expanding indications.

FAQs

1. What are the main therapeutic uses of triamcinolone acetonide?
It treats inflammatory and allergic conditions, including dermatitis, arthritis, asthma, and oral lesions.

2. How has patent expiry affected market prices?
Prices have decreased substantially, with generic versions available at lower costs.

3. Which regions present the most growth opportunities?
Emerging markets in Asia, Latin America, and Africa show increased demand due to rising healthcare access.

4. What is the outlook for new formulations?
R&D focuses on long-acting injectable versions and combination therapies, though commercialization is limited.

5. How does competition influence future profitability?
Intense generic competition maintains low prices, constraining profit margins but supporting volume growth.

---

References

[1] MarketsandMarkets. (2022). Corticosteroids Market. Retrieved from https://www.marketsandmarkets.com/
[2] IQVIA. (2022). The Global Use of Medicines in 2022.
[3] U.S. Food & Drug Administration. (2022). Approval and Regulation of Corticosteroid Products.
[4] European Medicines Agency. (2022). Evaluation of Generic Corticosteroids.
[5] S&P Global Market Intelligence. (2023). Pharmaceutical Competitive Landscape Data.